Novartis circles back with new terms for a stem cell biotech buyout – report – FierceBiotech

GlobesNovartis circles back with new terms for a stem cell biotech buyout - reportFierceBiotechNovartis' on-again, off-again deal to buy out Israeli stem cell therapy developer Gamida Cell is reportedly back on again--though the pharma giant has apparently renegotiated the old $600 million pact to include a smaller upfront buy-in and one of its ...Novartis To Invest In Gamida Cell Before AcquistionNoCamels - Israeli Innovation NewsNovartis to Invest Heavily in Gamida CellJewish Business Newsall 5 news articles
http://blog.zandcell.com/novartis-circles-back-with-new-terms-for-a-stem-cell-biotech-buyout-report-fiercebiotech/?utm_source=rss&utm_medium=rss&utm_campaign=novartis-circles-back-with-new-terms-for-a-stem-cell-biotech-buyout-report-fiercebiotech